Timms Olinda
Adjunct Faculty, Division of Health and Humanities, St Johns Research Institute, Bangalore 560 034, Karnataka, India.,
Indian J Med Ethics. 2018 Oct-Dec;3(4):289-292. doi: 10.20529/IJME.2018.085.
With India only just emerging out of a period of extreme concern and apprehension over clinical trials, the introduction of Controlled Human Infection Model (CHIM) studies calls for the need to proceed with caution, particularly with regard to protection of participants; especially vulnerable populations. In the Indian context, persons can be vulnerable due to circumstances of poverty, ignorance about clinical research and lack of access to education and healthcare. This paper will look at possible ways to provide protection to participants, starting with review and selection, through the trial period and after it is completed.
印度刚刚从一段对临床试验极度担忧和忧虑的时期走出来,引入人类感染控制模型(CHIM)研究需要谨慎行事,尤其是在保护参与者方面,特别是弱势群体。在印度的背景下,由于贫困、对临床研究的无知以及缺乏受教育和医疗保健的机会,人们可能会处于弱势地位。本文将探讨为参与者提供保护的可能方法,从审查和筛选开始,贯穿试验期及试验结束后。